5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Improved cardiovascular risk prediction using targeted plasma proteomics in primary prevention

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Aims

          In the era of personalized medicine, it is of utmost importance to be able to identify subjects at the highest cardiovascular (CV) risk. To date, single biomarkers have failed to markedly improve the estimation of CV risk. Using novel technology, simultaneous assessment of large numbers of biomarkers may hold promise to improve prediction. In the present study, we compared a protein-based risk model with a model using traditional risk factors in predicting CV events in the primary prevention setting of the European Prospective Investigation (EPIC)-Norfolk study, followed by validation in the Progressione della Lesione Intimale Carotidea (PLIC) cohort.

          Methods and results

          Using the proximity extension assay, 368 proteins were measured in a nested case–control sample of 822 individuals from the EPIC-Norfolk prospective cohort study and 702 individuals from the PLIC cohort. Using tree-based ensemble and boosting methods, we constructed a protein-based prediction model, an optimized clinical risk model, and a model combining both. In the derivation cohort (EPIC-Norfolk), we defined a panel of 50 proteins, which outperformed the clinical risk model in the prediction of myocardial infarction [area under the curve (AUC) 0.754 vs. 0.730; P < 0.001] during a median follow-up of 20 years. The clinically more relevant prediction of events occurring within 3 years showed an AUC of 0.732 using the clinical risk model and an AUC of 0.803 for the protein model ( P < 0.001). The predictive value of the protein panel was confirmed to be superior to the clinical risk model in the validation cohort (AUC 0.705 vs. 0.609; P < 0.001).

          Conclusion

          In a primary prevention setting, a proteome-based model outperforms a model comprising clinical risk factors in predicting the risk of CV events. Validation in a large prospective primary prevention cohort is required to address the value for future clinical implementation in CV prevention.

          Graphical Abstract

          Graphical Abstract

          Related collections

          Most cited references43

          • Record: found
          • Abstract: found
          • Article: not found

          Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.

          Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

              The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined.
                Bookmark

                Author and article information

                Journal
                Eur Heart J
                Eur Heart J
                eurheartj
                European Heart Journal
                Oxford University Press
                0195-668X
                1522-9645
                01 November 2020
                18 August 2020
                18 August 2020
                : 41
                : 41 , Focus Issue on Epidemiology and Prevention
                : 3998-4007
                Affiliations
                [e1 ]Department of Vascular Medicine, Amsterdam University Medical Centers, University of Amsterdam , Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
                [e2 ]Department of Cardiology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam , De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
                [e3 ]Department of Pharmacological and Biomolecular Sciences, University of Milan , Via Balzaretti 9, 20133 Milan, Italy
                [e4 ]Department of Cardiology, Amsterdam University Medical Centers, University of Amsterdam , Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
                [e5 ]Department of Public Health and Primary Care, University of Cambridge , 2 Worts' Causeway, Cambridge, UK
                [e6 ] Medical Research Council Epidemiology Unit , University of Cambridge, Cambridge CB2 0QQ, UK
                [e7 ] Multimedica IRCCS , Milano, Italy
                [e8 ] Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Technische Universität München , Munich, Germany
                [e9 ] DZHK (German Centre for Cardiovascular Research), Partner site Munich Heart Alliance , Munich, Germany
                [e10 ] Institute of Epidemiology and Medical Biometry, Ulm University , Ulm, Germany
                [e11 ] HorAIzon BV , Delft, the Netherlands
                Author notes

                Renate M. Hoogeveen and João P. Belo Pereira contributed equally to the study.

                Corresponding author. Tel: +31 20 5665978, Fax: +31 20 6968833, Email: e.s.stroes@ 123456amsterdamumc.nl
                Author information
                http://orcid.org/0000-0003-0292-9940
                http://orcid.org/0000-0001-9045-6009
                http://orcid.org/0000-0002-6216-1999
                http://orcid.org/0000-0002-8802-2903
                http://orcid.org/0000-0003-1422-2993
                http://orcid.org/0000-0002-7593-2094
                http://orcid.org/0000-0001-9555-6260
                Article
                ehaa648
                10.1093/eurheartj/ehaa648
                7672529
                32808014
                83eb0672-8730-4e70-9f80-d2850d478850
                © The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

                History
                : 14 November 2019
                : 13 February 2020
                : 27 July 2020
                : 21 July 2020
                Page count
                Pages: 10
                Funding
                Funded by: European Research Area Network on Cardiovascular Diseases;
                Award ID: ERA-CVD JTC2017
                Funded by: European Union’s Horizon 2020;
                Award ID: 667837
                Funded by: Cancer Research UK, DOI 10.13039/501100000289;
                Award ID: 14136
                Funded by: Medical Research Council, DOI 10.13039/501100000265;
                Award ID: G1000143
                Categories
                Clinical Research
                Epidemiology and Prevention
                Editor's Choice
                AcademicSubjects/MED00200

                Cardiovascular Medicine
                targeted proteomics,cardiovascular event risk,prediction,machine learning,proteomics,clinical risk score

                Comments

                Comment on this article